Search Results 211-220 of 17298 for hba1c

1. Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension - Mayo Clinic

   Uncontrolled diabetes mellitus (HbA1c >9%) within 3 months of screening; Significant systemic or major illness other than liver disease; HIV infection; Use of ...

2. Study Evaluating The Safety, Tolerability, And Effectiveness Of EDP-305 In Subjects With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

   ... HbA1c of at least 6% with or without concomitant treatment with metformin. AND. Screening MRI-PDFF with >8% steatosis;; Body mass index (BMI) >25 kg/m2. NOTE ...

3. Efficacy And Safety Of Intranasal Cenegermin In Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) - Mayo Clinic

   Uncontrolled diabetes mellitus (HbA1c ≥ 8.0%), any diabetic retinopathy, or previous pan-retinal laser photocoagulation or macular laser photocoagulation.

4. Study Of INCB053914 In Subjects With Advanced Malignancies - Mayo Clinic

   Part 1 and Part 3 only: Hemoglobin A1c (HbA1c) > 8.0% (all subjects will have HbA1c tested at screening). Part 1 and Part 3: Any history of disease ...

5. Low hemoglobin count Causes - Mayo Clinic

   A low hemoglobin count is a commonly seen blood test result. Hemoglobin (Hb or Hgb) is a protein in red blood cells that carries oxygen throughout the body.

6. A Study Of The Use Of A New Drug In People With Non-Alcoholic Steatohepatitis (NASH) Or Non-Alcoholic Fatty Liver Disease (NAFLD) - Mayo Clinic

   Subjects with type 2 diabetes who are on stable doses of medications (except pioglitazone) to control hyperglycemia and have baseline HbA1c of 10% or lower.

7. Exercise And Low-Dose Rapamycin In Older Adults With CAD:Cardiac Rehabilitation And Rapamycin In Elderly (CARE) Trial - Mayo Clinic

   HbA1c > 13%. Any malignancy; Hematological disorder, including thrombocytopenia, leucopenia. Noncardiac illness expected to limit survival. Chronic liver ...

8. Study Of Copanlisib In Combination With Standard Immunochemotherapy In Relapsed Indolent Non-Hodgkin's Lymphoma (INHL) - Mayo Clinic

   HbA1c > 8.5% at Screening. History or concurrent condition of interstitial lung disease and/or severely impaired lung function (as judged by the ...

9. LGX818 And MEK162 In Combination With A Third Agent (BKM120, LEE011, BGJ398 Or INC280) In Advanced BRAF Melanoma - Mayo Clinic

   Patients with fasting glucose > 120 mg/dL or 6.7 mmol/L, and HbA1c > 8 %. Patient has any of the following mood disorders as judged by the. Investigator or a ...

10. AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

    Uncontrolled diabetes defined as hemoglobin A1c (HbA1c) ≥ 8 or fasting blood glucose ≥ 140 mg/dL. Any of the following. History of significant ventricular ...